The approved monoclonal antibodies for CRC include epidermal growth factor receptor (EGFR)-targeting antibodies such as cetuximab and panitumumab and the vascular endothelial growth factor (VEGF)-targeting antibody bevacizumab. This evidence concerns the gene EGFR and colorectal carcinoma.